ACM
VRPX

Altium Capital Management’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Altium Capital Management’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,087
Closed -$1.3M – 165
2021
Q3 		$1.3M Buy
+1,087
New +$2.28M 0.34% 87

Other funds holding VRPX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Altium Capital Management's VRPX Position: Q4 2021 in Review

Altium Capital Management sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q4 2021, closing a stake of 1,087 shares — an estimated $1.3M sold.

Altium Capital Management first reported a position in VRPX in Q3 2021 and held it in 1 quarter. The position peaked at $1.3M in Q3 2021. 16 funds tracked by Wall St. Rank hold VRPX as of Q4 2021.

  • Altium Capital Management reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Altium Capital Management sold 1,087 Virpax Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $1.3M.
  • Altium Capital Management first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Altium Capital Management's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $1.3M in Q3 2021.
  • 16 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Altium Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.